Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded by StockNews.com to “Buy” Rating

StockNews.com upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a hold rating to a buy rating in a report published on Friday morning.

Other equities analysts have also issued research reports about the stock. Piper Sandler restated an “overweight” rating and set a $296.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Wolfe Research lowered Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday, November 12th. Scotiabank increased their price target on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a research note on Friday, November 1st. Barclays lifted their price objective on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. Finally, Chardan Capital reiterated a “buy” rating and set a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $298.09.

Alnylam Pharmaceuticals Trading Down 1.9 %

Alnylam Pharmaceuticals stock opened at $237.97 on Friday. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $304.39. The firm has a market capitalization of $30.69 billion, a price-to-earnings ratio of -90.83 and a beta of 0.32. The firm has a 50 day moving average of $259.89 and a 200 day moving average of $253.96.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. During the same period in the prior year, the company earned $1.15 earnings per share. The business’s revenue for the quarter was down 33.3% compared to the same quarter last year. As a group, research analysts predict that Alnylam Pharmaceuticals will post -2.21 earnings per share for the current year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,682 shares of the stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the transaction, the chief marketing officer now directly owns 17,457 shares in the company, valued at $4,381,357.86. This represents a 8.79 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Tolga Tanguler sold 1,469 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the transaction, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at $3,310,677.18. This trade represents a 10.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,122 shares of company stock worth $2,540,455 in the last three months. Corporate insiders own 1.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Souders Financial Advisors grew its stake in shares of Alnylam Pharmaceuticals by 1.0% during the 2nd quarter. Souders Financial Advisors now owns 3,512 shares of the biopharmaceutical company’s stock worth $853,000 after purchasing an additional 36 shares during the period. Huntington National Bank grew its position in Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 45 shares during the period. SYM FINANCIAL Corp increased its holdings in Alnylam Pharmaceuticals by 6.2% in the third quarter. SYM FINANCIAL Corp now owns 947 shares of the biopharmaceutical company’s stock valued at $260,000 after buying an additional 55 shares in the last quarter. Lindbrook Capital LLC raised its position in shares of Alnylam Pharmaceuticals by 11.1% in the third quarter. Lindbrook Capital LLC now owns 570 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 57 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its stake in shares of Alnylam Pharmaceuticals by 54.2% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 259 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 91 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.